Skip to content

Trial Summary

This phase 2 randomised clinical trial will compare the effectiveness of Lu-PSMA therapy followed by docetaxel chemotherapy versus docetaxel chemotherapy on its own in patients with newly-diagnosed high-volume metastatic hormone-naive prostate cancer (mHNPC).

Acronym:

UpFrontPSMA

ACTRN/NCT /ethics:

NCT04343885

Scientific title:

UpFrontPSMA : A Randomised Phase 2 Study of Sequential 177Lu-PSMA617 and Docetaxel Versus Docetaxel in Metastatic Hormone-Naive Prostate Cancer

Sponsor / Cooperative group:

Peter MacCallum Cancer Centre, Australia

Trial & Patient Characteristics

Cancer TypeProstate
Trial TypeTreatment
PhasePhase II
Age Range18 years and older
SexMale
Tumour Stream Prostate
Cancer StageMetastatic or Widespread
Anticipated Start Date21/04/2020
Anticipated End Date1/04/2024

Participating Hospitals

HospitalRoyal Adelaide Hospital
Clinical Trial CoordinatorAnne Milton
Emailanne.milton@sa.gov.au
Phone08 7074 2342
Principal InvestigatorDr Hsiang Tan
Recruitment StatusNot Yet Recruiting